As a Gold Sponsor, SERENE Pharma hosted a dedicated satellite symposium examining contemporary approaches to cardiovascular prevention and chronic heart failure management.
A Milestone for Cardiovascular Medicine
On 2 October 2026, the Uzbekistan Cardiologists’ Conference, “Modern Cardiology: From Prevention to Advanced Technologies,” featured a scientific program dedicated to the 50th anniversary of the Republican Specialized Scientific and Practical Medical Center of Cardiology. The program brought together medical specialists to discuss advances in coronary artery disease, hypertension, cardiovascular risk reduction, and heart failure management.
SERENE Pharma’s Gold Sponsorship and Satellite Symposium
SERENE Pharma participated as a Gold Sponsor and hosted a satellite symposium on 2 October in the Amir Timur Hall, from 14:40 to 15:30. The company-supported session focused on two areas of clinical importance: lipid-modifying therapy for cardiovascular event prevention and evidence-based treatment of chronic heart failure.
Scientific Presentations at the SERENE Satellite Symposium
Associate Professor Ikbol Gafuritdinovna Adilova, from the Department of Cardiology and Gerontology with a Course in Interventional Cardiology and Arrhythmology at the Center for the Development of Professional Qualifications of Medical Workers, presented “The Evolution of Lipid-Modifying Therapy: Why Rosuvastatin Remains a Cornerstone in the Prevention of Cardiovascular Events.” Her session ran from 14:40 to 15:05.
Professor Gavkhar Mirakbarovna Tulabaeva, Head of the same department, followed from 15:05 to 15:30 with “Sacubitril/Valsartan in Contemporary Management of Chronic Heart Failure: From Evidence to Clinical Practice.” Together, the presentations highlighted contemporary scientific approaches to preventing cardiovascular events and managing patients with chronic heart failure.
A Wider Program of Cardiovascular Research
The conference agenda also included sessions on modern technologies for treating chronic coronary artery disease, outcomes of stenting in patients with ST-segment elevation acute coronary syndrome, management of arterial hypertension with attention to cardiorenometabolic risk, and antihypertensive treatment in patients with comorbidities. These presentations were part of the broader conference program; the supplied agenda specifically identifies the two lectures above as the SERENE satellite symposium.
Supporting Continuing Medical Education
Through its Gold Sponsorship and focused scientific session, SERENE Pharma supported a platform for professional dialogue on current cardiovascular treatment approaches. Such engagement reflects the company’s commitment to scientific communication and continuing medical education, with the aim of strengthening relationships with healthcare professionals and contributing to evidence-informed clinical practice in Uzbekistan.
Looking Ahead
The conference marked an opportunity for SERENE Pharma to engage with the cardiology community and support discussion of important therapeutic developments. The company looks forward to continued participation in scientific and educational initiatives that advance professional knowledge and patient care.
SERENE Pharma — Science for Happiness.
